BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mukherjee A, Madamsetty VS, Paul MK, Mukherjee S. Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer. Int J Mol Sci 2020;21:E455. [PMID: 31936832 DOI: 10.3390/ijms21020455] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Codony VL, Tavassoli M. Hypoxia-induced therapy resistance: Available hypoxia-targeting strategies and current advances in head and neck cancer. Transl Oncol 2021;14:101017. [PMID: 33465746 DOI: 10.1016/j.tranon.2021.101017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Li Q, Zhou R, Sun Y, Xiao D, Liu M, Zhao D, Peng S, Chen Y, Lin Y. Synthesis and Antitumor Application of Antiangiogenetic Gold Nanoclusters. ACS Appl Mater Interfaces 2021;13:11708-20. [PMID: 33656845 DOI: 10.1021/acsami.1c01164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sharifi-Rad J, Quispe C, Patra JK, Singh YD, Panda MK, Das G, Adetunji CO, Michael OS, Sytar O, Polito L, Živković J, Cruz-Martins N, Klimek-Szczykutowicz M, Ekiert H, Choudhary MI, Ayatollahi SA, Tynybekov B, Kobarfard F, Muntean AC, Grozea I, Daştan SD, Butnariu M, Szopa A, Calina D. Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy. Oxid Med Cell Longev 2021;2021:3687700. [PMID: 34707776 DOI: 10.1155/2021/3687700] [Reference Citation Analysis]
4 Rajora AK, Ravishankar D, Zhang H, Rosenholm JM. Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy. Pharmaceutics 2020;12:592. [DOI: 10.3390/pharmaceutics12060592] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
5 Ashrafizadeh M, Najafi M, Ang HL, Moghadam ER, Mahabady MK, Zabolian A, Jafaripour L, Bejandi AK, Hushmandi K, Saleki H, Zarrabi A, Kumar AP. PTEN, a Barrier for Proliferation and Metastasis of Gastric Cancer Cells: From Molecular Pathways to Targeting and Regulation. Biomedicines 2020;8:E264. [PMID: 32756305 DOI: 10.3390/biomedicines8080264] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
6 Liang P, Ballou B, Lv X, Si W, Bruchez MP, Huang W, Dong X. Monotherapy and Combination Therapy Using Anti-Angiogenic Nanoagents to Fight Cancer. Adv Mater 2021;33:e2005155. [PMID: 33684242 DOI: 10.1002/adma.202005155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
7 Nurcahyanti ADR, Jap A, Lady J, Prismawan D, Sharopov F, Daoud R, Wink M, Sobeh M. Function of selected natural antidiabetic compounds with potential against cancer via modulation of the PI3K/AKT/mTOR cascade. Biomed Pharmacother 2021;144:112138. [PMID: 34750026 DOI: 10.1016/j.biopha.2021.112138] [Reference Citation Analysis]
8 Dutta B, Barick KC, Hassan PA. Recent advances in active targeting of nanomaterials for anticancer drug delivery. Adv Colloid Interface Sci 2021;296:102509. [PMID: 34455211 DOI: 10.1016/j.cis.2021.102509] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhu D, Li Y, Zhang Z, Xue Z, Hua Z, Luo X, Zhao T, Lu C, Liu Y. Recent advances of nanotechnology-based tumor vessel-targeting strategies. J Nanobiotechnology 2021;19:435. [PMID: 34930293 DOI: 10.1186/s12951-021-01190-y] [Reference Citation Analysis]
10 Ashrafizadeh M, Gholami MH, Mirzaei S, Zabolian A, Haddadi A, Farahani MV, Kashani SH, Hushmandi K, Najafi M, Zarrabi A, Ahn KS, Khan H. Dual relationship between long non-coding RNAs and STAT3 signaling in different cancers: New insight to proliferation and metastasis. Life Sci 2021;270:119006. [PMID: 33421521 DOI: 10.1016/j.lfs.2020.119006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
11 Wang Y, Chen T, Li K, Mu W, Liu Z, Shi A, Liu J, Zhao W, Lian S, Huang S, Pan C, Zhang Z. Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer. Front Oncol 2021;11:777617. [PMID: 34778094 DOI: 10.3389/fonc.2021.777617] [Reference Citation Analysis]
12 Zadorozhna M, Mangieri D. Mechanisms of Chemopreventive and Therapeutic Proprieties of Ginger Extracts in Cancer. Int J Mol Sci 2021;22:6599. [PMID: 34202966 DOI: 10.3390/ijms22126599] [Reference Citation Analysis]
13 Su J, Zhu H, Yao Y, Duan Y. Antiangiogenic Therapy: Challenges and Future Directions. CTMC 2021;21:87-9. [DOI: 10.2174/156802662102201211113414] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
14 Kazakova O, Șoica C, Babaev M, Petrova A, Khusnutdinova E, Poptsov A, Macașoi I, Drăghici G, Avram Ș, Vlaia L, Mioc A, Mioc M, Dehelean C, Voicu A. 3-Pyridinylidene Derivatives of Chemically Modified Lupane and Ursane Triterpenes as Promising Anticancer Agents by Targeting Apoptosis. Int J Mol Sci 2021;22:10695. [PMID: 34639035 DOI: 10.3390/ijms221910695] [Reference Citation Analysis]
15 Xu B, Zhang Y, Yang H, Liu T, Lu Y, Xu Y, Zhang Q, Li X, Huang Z, Zhang Y, Webster TJ. siVEGF-loaded nanoparticle uptake by tumor-associated vascular endothelial cells for hepatocellular carcinoma. Nanomedicine (Lond) 2020. [PMID: 32458768 DOI: 10.2217/nnm-2020-0082] [Reference Citation Analysis]
16 Lee S, Kim S, Koo DJ, Yu J, Cho H, Lee H, Song JM, Kim SY, Min DH, Jeon NL. 3D Microfluidic Platform and Tumor Vascular Mapping for Evaluating Anti-Angiogenic RNAi-Based Nanomedicine. ACS Nano 2021;15:338-50. [PMID: 33231435 DOI: 10.1021/acsnano.0c05110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
17 Ashrafizadeh M, Zarrabi A, Hashemi F, Moghadam ER, Hashemi F, Entezari M, Hushmandi K, Mohammadinejad R, Najafi M. Curcumin in cancer therapy: A novel adjunct for combination chemotherapy with paclitaxel and alleviation of its adverse effects. Life Sci 2020;256:117984. [PMID: 32593707 DOI: 10.1016/j.lfs.2020.117984] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
18 Paskeh MDA, Mirzaei S, Orouei S, Zabolian A, Saleki H, Azami N, Hushmandi K, Baradaran B, Hashmi M, Aref AR, Ertas YN, Zarrabi A, Ashrafizadeh M, Samarghandian S. Revealing the role of miRNA-489 as a new onco-suppressor factor in different cancers based on pre-clinical and clinical evidence. Int J Biol Macromol 2021;191:727-37. [PMID: 34562537 DOI: 10.1016/j.ijbiomac.2021.09.089] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Bi J, Dixit G, Zhang Y, Devor EJ, Losh HA, Newtson AM, Coleman KL, Santillan DA, Maretzky T, Thiel KW, Leslie KK. Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy. Pharmaceuticals (Basel) 2021;14:682. [PMID: 34358108 DOI: 10.3390/ph14070682] [Reference Citation Analysis]
20 Liu Y, Huang N, Liao S, Rothzerg E, Yao F, Li Y, Wood D, Xu J. Current research progress in targeted anti-angiogenesis therapy for osteosarcoma. Cell Prolif 2021;:e13102. [PMID: 34309110 DOI: 10.1111/cpr.13102] [Reference Citation Analysis]
21 Wilson RL, Jones HN. Targeting the Dysfunctional Placenta to Improve Pregnancy Outcomes Based on Lessons Learned in Cancer. Clin Ther 2021;43:246-64. [PMID: 33446335 DOI: 10.1016/j.clinthera.2020.12.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Briolay T, Petithomme T, Fouet M, Nguyen-Pham N, Blanquart C, Boisgerault N. Delivery of cancer therapies by synthetic and bio-inspired nanovectors. Mol Cancer 2021;20:55. [PMID: 33761944 DOI: 10.1186/s12943-021-01346-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]